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Purpose: Solid lipid nanoparticles are largely used in biomedical research and are char-
acterized by high stability and biocompatibility and are also able to improve the stability of
various loaded molecules. In vitro studies demonstrated that these nanoparticles are low
cytotoxic, while in vivo studies proved their efficiency as nanocarriers for molecules
characterized by a low bioavailability. However, to our knowledge, no data on the systemic
biodistribution and organ accumulation of solid lipid nanoparticles in itself are presently
available.
Methods: In this view, we investigated the solid lipid nanoparticles biodistribution by
a multimodal imaging approach correlating in vivo and ex vivo analyses. We loaded solid
lipid nanoparticles with two different fluorophores (cardiogreen and rhodamine) to observe
them with an optical imager in the whole organism and in the excised organs, and with
fluorescence microscopy in tissue sections. Light and transmission electron microscopy
analyses were also performed to evaluate possible structural modification or damage due
to nanoparticle administration.
Results: Solid lipid nanoparticles loaded with the two fluorochromes showed good optic
characteristics and stable polydispersity. After in vivo administration, they were clearly detect-
able in the organism. Four hours after the injection, the fluorescent signal occurred in anatomical
districts corresponding to the liver and this was confirmed by the ex vivo acquisitions of excised
organs. Brightfield, fluorescence and transmission electron microscopy confirmed solid lipid
nanoparticles accumulation in hepatocytes without structural damage.
Conclusion: Our results support the systemic biocompatibility of solid lipid nanoparticles
and demonstrate their detailed biodistribution from the whole organism to organs until the
cells.
Keywords: lipid-based nanoparticles, systemic biodistribution, optical imaging, light
microscopy, transmission electron microscopy, tissue accumulation
Introduction
Biocompatibility is a basic issue in nanotechnology, especially with regard to
nanoconstructs intended for medical use. In this view, lipid-based nanoparticles
have attracted great attention as versatile tools with a high potential of medical
applications due to their natural components.1–3
Solid lipid nanoparticles (SLN) currently represent a great promise for drug
delivery, clinical medicine and research since they are characterized by high
stability and biocompatibility, and already for a long time the synthesis of these
nanoconstructs sparked great interest.4,5 The lipid excipients used for their produc-
tion have, in fact, well-established safety profiles and are largely employed in FDA
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approved products.6,7 In addition, due to the physicochem-
ical properties of lipids (ie, low melting temperature), SLN
can be easily obtained by direct emulsification of the
molten lipids and subsequent recrystallization, avoiding
the use of potentially toxic solvents. SLN are also able to
improve the stability of various loaded molecules, increas-
ing their bioavailability and assuring restrained release
profile.2,8-14 SLN maintain their physical stability for
a long time and can be administered by different routes,
including the oral or intranasal one.15,16
The effects of SLN on living cells have been tested in
many in vitro studies, confirming their low cytotoxicity.17,18
As for SLN administered in vivo, the large majority of
studies focused on their efficiency as nanocarriers for mole-
cules that have low bioavailability or poor water solubility,
or high chemical and metabolic instability; SLN have been
studied also for their capability to overcome biological
barriers (eg, by functionalizing their surface with polysor-
bate 80).19–25
However, to our knowledge, no data on the systemic
biodistribution and organ accumulation of SLN in itself
are presently available.26 This is a basic information for
their systemic use since, although SLN are made of fully
biocompatible components, their in vivo fate may depend
on a variety of factors related to the administration route
and to the interactions with the complex and heteroge-
neous biological environment of a living organism.6,27
In this view, we investigated the biodistribution of SLN
by a multimodal imaging approach correlating in vivo and ex
vivo analyses. To this aim, we prepared fluorescent SLN
loaded with two different fluorophores, namely cardiogreen
(CG) detectable with an optical imager in the whole organism
and in the excised organs, and rhodamine (RH) detectable in
tissue sections with fluorescence microscopy. The fluorescent
SLN were injected intraperitoneally in mice to analyse their
biodistribution kinetics in vivo and their accumulation in key
organs ex vivo. Histological and ultrastructural analyses were
also performed in order to evaluate possible structural
damage due to nanoparticle administration. Moreover, SLN
uptake and intracellular fate were investigated in cultured
cells to support the in vivo and ex vivo evidence.
Materials and Methods
Spectroscopical Analysis
Cardiogreen (indocyanine green, Sigma Aldrich, St Louis,
MO, USA) (CG) and rhodamine (5(6)-carboxy-X-rhod
amine, Sigma) (RH) were analyzed as ethanol solution or
SLN dispersion. The UV–VIS spectra were recorded using
a Josio V570® dual-beam spectrophotometer equipped with
W/I2 and H2/D2 lamps, in NIR/VIS and UV, respectively. The
emission and excitation fluorescence spectra were recorded
with an ISA FLUOROMAX® spectrofluorimeter equipped
with R1527P photomultiplier and xenon lamp.
Production of Solid Lipid Nanoparticles
SLN, constituted of tristearin (glyceryl tristearate, Fluka,
Buchs, Switzerland) (5% w/w, with respect to the whole
weight of the dispersion, were prepared by melt and ultra-
sonication method, as reported in.28 Briefly, nanoparticles
were produced by adding to the molten lipid Phase
4.75 mL of an aqueous poloxamer 188 solution (copoly-
mer poly (ethylene oxide) (a) – poly (propylene oxide,
BASF ChemTrade GmbH, Burgbernheim, Germany) (b)
(a=80, b=27), 2.5% w/w) heated at 80°C. The mixture was
then emulsified at 15,000 rpm, 80°C for 1 min, using
a high-speed homogenizer (UltraTurrax T25, IKA-Werke
GmbH & Co. KG, Staufen, Germany). Afterwards, the
emulsion was subjected to ultra-sonication (Microson
TM, Ultrasonic cell Disruptor) at 6.75 kHz for 15 min
and then let cooling at room temperature. The obtained
SLN dispersions were maintained at room temperature
until used. Fluorescent nanoparticles were produced with
the same procedure, adding the fluorophore (CG or RH or
both, 0.02% w/w with respect to the weight of the lipids)
to the molten tristearin (Fluka). SLN preparations were
named as follows: SLN-E (empty, control SLN), SLN-
RH (SLN-containing RH), SLN-CG (SLN-containing
CG), SLN-RH/CG (SLN-containing both RH and CG).
Characterization of Solid Lipid
Nanoparticles
In order to identify possible agglomeration or sedimentation
phenomena, the SLN dispersions were visually inspected
each day up to 30 days, from the preparation. SLN size
analysis was performed using a Zetasizer Nano-S90
(Malvern Instr., Malvern, England) equipped with a 4 mW
helium-neon laser with a wavelength output of 633 nm. The
sample preparation procedure was carried out in a laminar
airflow bench, using single-use syringes, needles, and pipette
tips.Measurements weremade at 25°C, placing the samples in
the machine for 5 min prior to the start of measurements to
eliminate temperature differences between the sample and the
machine, at an angle of 90°. Data were interpreted using the
“CONTIN” method.28 SLN morphology was investigated by
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means of cryogenic transmission electron microscopy (cryo-
TEM). Samples were vitrified and transferred to a Zeiss
EM922Omega transmission electron microscope for imaging
using a cryoholder (CT3500, Gatan).29 Specimens were
examined with doses of about 1000–2000 e/nm2 at 200 kV.
A CCD camera (Ultrascan 1000, Gatan) was used to record
the digital images. The separation of fluorescent nanoparticles
from free fluorophores and the determination of fluorescence
content of nanoparticles were made as previously reported.30
Briefly, 300 µl of nanoparticle samples were loaded in
a centrifugal filter (Microcon unit YM-10 membrane,
NMWCO 10 kDa, Sigma) and subjected to centrifugation at
8,000 rpm for 60 min using a Spectrafuge™ 24D Digital
Microcentrifuge (Woodbridge NJ, USA). Afterwards, the
fluorescence in the eluate was determined by fluorescence
spectroscopy, taking as reference a previously made calibra-
tion curve allowing the determination of the encapsulation
efficiency (EE) and loading capacity (LC). The association
of fluorophores to lipid nanoparticle was verified by using
thin-layer chromatography (TLC) silica gel 60 F254 (Merck
KGaA, Darmstadt, Germany) with an imaging plate (BAS-
SR2040, FujiFilm, Tokyo, Japan) and a fluorescence imaging
system (photodynamic eye (PDE); Hamamatsu Photonics,
Hamamatsu, Japan). TLC was performed eluting 5 μL of the
fluorescent sample (either nanoparticle or solution) applied on
the silica plate with mixtures of ethanol/water. Afterwards, the
fluorescent spots were quantified putting the plates on the
imaging plate and scanning them using a phosphor imager
FLA-2000 (FujiFilm). Fluorescence levels were visualized
from the display.
The zeta potential was measured by electrophoretic mobi-
lity of the particles using a ZetaSizer Nano ZS (Malvern
Instruments, UK). Samples were diluted approximately 100
fold with ultrapure water resulting in a conductivity of 50 ± 5
μS cm−1.
In vivo and ex vivo Optical Imaging
For the biodistribution study, 18 male athymic nude mice
(Harlan Laboratories, Italy), 4–5 weeks old and about 25
g in weight, were used. Athymic nude mice were chosen to
allow the detection of faint light signals coming from dee-
pest anatomical districts, thanks to the absence of fur and
hair bulbs, which are both high absorbers and sources of
light scattering. A limited but statistically significant num-
ber of animals were used for ethical reasons. Mice were
housed in a temperature- and humidity-controlled environ-
ment, having free access to mouse chow and tap water.
Light conditions were maintained on 12 h-cycle. Animals
were handled according to the regulations of the Italian
Ministry of Health (DL March, 4 2014, n. 26, directive
implementation 2010/63/UE) and to the European
Communities Council (Directive 63/2010/EU of the
European Parliament and of the Council) directives.
Project code approved by Italian Ministry of Health is
Calderan 18,052. Mice were divided into three groups: the
first one (n=6) was administered with an intraperitoneal (ip)
500 µL injection of fluorescent SLN labelled with CG
(SLN-CG) (50mg/mL in lipid phase), the second one
(n=6) was administered with an ip 500 µL injection of
fluorescent SLN labelled with both CG and RH (SLN-RH
/CG) (50 mg/mL in lipid phase), the third one (n=6, control
group) was administered with an ip 500 µL injection of sole
SLN dispersing phase composed of aqueous poloxamer 188
solution (2.5% w/w) (Sigma). The amount of the injected
SLN was determined by preliminary experiments demon-
strating that a lower amount was undetectable by optical
imager (not shown). During injection and image acquisi-
tion, mice were kept under gas anesthesia (2% of isoflurane
and 1 mL/min of oxygen). Mice were imaged 5, 15, 30, 60,
120, 180, and 240 min after SLN ip injection. These time
points allowed to monitor the systemic biodistribution and
tissue accumulation of SLN after administration. The time
of SLN clearance depends on many parameters such as the
nanoparticle composition, size and opsonization, and the
route of administration. In particular, the adsorption of
plasma proteins, which determines the ultimate fate of the
SLNs in the organism (ie, phagocytosis, prolonged circula-
tion or tissue targeting), is affected by both the plasma
protein concentration and the surface properties of SLN.
Anyway, it is likely that the complete elimination of lipid
nanoparticles from the organism may take place in a few
hours.
Optical images were acquired with IVIS Spectrum
(Perkin Elmer, Waltham, MA, USA) in fluorescent mod-
ality with excitation filter 710 nm and emission filter 800
nm. Other parameters were exposure time 1 s, binning
B=4, f/stop= 2. After nanoparticles injection, the biodis-
tribution was monitored separately with regard to SLN-CG
and SLN-CG/RH. Measurements were done tracing
a Region of interest (ROI) on the fluorescent images in
correspondence of the abdominal region of the animals.
The results are reported as fold of increase of the mean
radiance normalized to the pre-injection emitted radiance.
Since the comparison of biodistribution revealed no dif-
ference between SLN-CG and SLN-CG/RH, all the sub-
sequent analyses were performed using the double-labelled
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SLN. After the last step of acquisition, mice were sacri-
ficed through an anesthetic overdose and then perfused
with 4% paraformaldehyde (Sigma) in 0.1 M phosphate
buffer saline (PBS), pH 7.4. After perfusion, liver, kidney,
lungs (organs involved in the elimination process), spleen
(located in the fluorescent abdomen area), brain (SLN
hypothetical target organ), and interscapular brown adi-
pose tissue (hypothetical target organ as a lipid accumulat-
ing tissue) were excised and imaged with the same
parameters as for the in vivo acquisitions. Finally, the
organs were processed for light microscopy and TEM
analyses.
Light Microscopy ex vivo Analyses
Excised liver (where in vivo and ex vivo optical imaging
analysis revealed an evident fluorescent signal) were cut into
small fragments and processed for light (brightfield and
fluorescence) microscopy. The samples were further fixed
by immersion with 4% paraformaldehyde (Sigma) in 0.1
M PBS, pH 7.4, overnight at 4°C, rinsed in PBS, and put
into 30% sucrose overnight. Subsequently, the tissues were
embedded in OCT (Optimal Cutting Temperature) com-
pound (DDK srl, Milan Italy), immediately frozen in isopen-
tane (Sigma) cooled down in liquid nitrogen, and stored at
−80°C until cutting. Seven-µm-thick cryostat sections were
stained with 1 µg/mL Hoechst 33,342 (Sigma) in PBS to be
observed at fluorescence microscopy. An Olympus BX51
microscope equipped with a 100 W mercury lamp
(Olympus Italia Srl, Segrate, MI, Italy) was used under the
following conditions: 540 nm excitation filter (excf), 580 nm
dichroic mirror (dm), and 620 nm barrier filter (bf), for red
fluorescence; 330–385 nm excf, 400 nm dm, and 420 nm bf,
for Hoechst 33,342. Brightfield images of the same fields
acquired at fluorescence microscopy were also taken. Images
were recorded with a QICAM Fast 1394 digital camera
(QImaging, Surrey, BC, Canada) and processed using Image-
Pro Plus 7.0 software (Media Cybernetics Inc., Rockville,
MD USA). Since SLN were found only in the liver, sections
of this tissue were stained with 0.5% Oil Red O (Bio Optica,
Milan, Italy) to visualized possible lipid accumulation, coun-
terstained with Mayer’s hematoxylin solution (Sigma), and
observed at brightfield microscopy (technical details in31).
Transmission Electron Microscopy ex vivo
Analyses
In order to verify the high-resolution structural preservation
of the hepatic tissue, a TEM analysis was performed. Small
fragments (about 1 mm3) of the excised livers were further
fixed with 2% paraformaldehyde (Sigma) and 2.5% glutar-
aldehyde (Electron Microscopy Sciences, Fort Washington,
PA, USA) in 0.1 M PBS for 2 h at 4°C, post-fixed in 1%
osmium tetroxide in aqueous solution for 2 h at 4°C, dehy-
drated in graded concentrations of acetone and embedded in
an Epon-Araldite mixture (Electron Microscopy Sciences).
Semithin 2-µm-thick sections were stained with 1% aqueous
solution of toluidine blue (Sigma) and observed at brightfield
microscopy to select centrilobular regions, where ultrathin
70-nm-thick sections were cut. The samples were observed
in a Philips Morgagni transmission electron microscope (FEI
Company, Thermo Fisher Scientific, Hillsboro, OR, USA),
operating at 80 kVand equipped with a MegaView II camera
(EMSIS GmbH, Muenster, Germany) for digital image
acquisition.
In vitro Analysis
In order to monitor the intracellular fate of SLN under
controlled conditions, an in vitro model was used. 3T3
cells, a fibroblast established cell line (ECACC, Sigma),
were grown in Dulbecco’s modified Eagle’s medium nutri-
ent mixture F12 containing 10% foetal bovine serum and
1% penicillin/streptomycin, at 37°C in a 5% CO2 humidi-
fied atmosphere. Cells were trypsinized (0.25% trypsin in
PBS containing 0.05% EDTA) when about 70% confluent
(all reagents for cell culture were from Celbio, Milan,
Italy). For analyses at light microscopy and TEM, cells
were seeded on glass coverslips placed in 6-multiwell
plates (5×104 cells per well) (Corning Inc., Corning, NY,
USA). After 24 h, the medium was replaced with fresh
medium containing 0.5 mg/mL of SLN (this concentration
was chosen based on the biocompatibility data).32 The
cells were incubated for 1 h, 4 h, and 24 h in order to
verify the occurrence of a time-dependent effect. At each
time point, for light microscopy the cells were fixed with
4% buffered paraformaldehyde (Sigma), and stained with
Oil Red O (Bio Optica) and Mayer’s hematoxylin solution
(Sigma), as described for tissue samples. For TEM, the
cells were fixed, embedded and stained as described for
liver samples.
Statistical Analysis
Statistical analysis was performed by the analysis of var-
iance (ANOVA) considering P-values <0.05 as the level of
significance.
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Results
Spectroscopic Study
This investigation presents the systemic biodistribution
and organ accumulation of SLN studied in vivo and ex
vivo by fluorescent modality with two instruments,
namely: an in vivo imaging system operating at 740 nm
excitation and 800 nm emission wavelength and an in vitro
system with 560 nm excitation and 590 emission filters
(see details in the experimental section).
In this respect, it has become necessary an appropriate
selection of fluorophores: the dyes should indeed possess
specific properties, including a low molecular weight and
lipophilic character (to be efficiently encapsulated in SLN),
and spectral profiles compatible with the detection systems
above reported. Specifically, the following fluorophores have
been selected: RH (λexc = 540 nm and λabs = 565 nm) and CG
(λexc= 690 nm and λabs = 787 nm). To test the chosen mole-
cules, a preliminary study has been performed in order to
verify interference phenomena after concomitantly loading
both fluorophores into SLN. It is indeed known that when
two or more fluorophores are co-solubilized (or co-embedded
in the same particle), they may interfere each other by energy
transfer that could lead to a shutdown of the one with the
lower adsorption wavelength (ie, RH in our case). Therefore,
the spectra of RH and CG as ethanol solutions either as single
molecular species or in mixture solutions were recorded.
Figure 1 (panels A and B) reports the absorption spectra of
RH and CG, showing for RH a λmax(abs) = 787 nm and ε =
192,000 and for CG a λmax(abs) = 565 nm and ε = 100,000. In
addition, the panel C of Figure 1 reports the emission spectra
of both dyes, firstly measured as single molecules in solution:
RH, λex= 540 nm (red line); CG, λex= 690 nm (black line) and
later as 1:1 (w/w) mixture: RH+CG, λex= 540 nm (blue line);
RH+CG, λex= 690 nm (green line). The reported data demon-
strated that after excitation at the typical wavelengths of both
molecules, the fluorophoresmaintain their spectral absorption/
emission properties, notably RH is not shut down by the
presence of CG thus no energy transfer between the fluoro-
phores was observed. These preliminary results were followed
by the design and preparation of SLN containing a single
fluorophore (RH or CG) as well as SLN simultaneously con-
taining both dyes, as described in the following paragraph.
Preparation and Characterization of
Fluorescent SLN
SLN were prepared by a two-step protocol based on the
emulsification under high-speed stirring (15,000 rpm) of an
aqueous solution of poloxamer 188 in the molten lipids,
followed by probe ultrasonication. After preparation, all
SLN dispersions display a homogeneous aspect free from
agglomerates or sediment. SLN-RH and SLN-CG disper-
sions, due to the presence of the dyes, resulted slightly
colored (ie, red or green depending on the encapsulated
fluorophore). In the case of SLN-RH/CG, the color of the
dispersion resulted from the sum of CG and RH colors. The
emission spectra registered for SLN-RH and SLN-CG
(reported in Figure 2A and B), confirm the behavior above
described (ie, for the fluorophores in ethanol solution), inter-
estingly the emission spectra of both RH and CG in SLN
display the maximum at slightly higher value (both are
shifted by 20–50 nm, toward the red region), in reason of
the different environment in which the fluorophores are
located, namely SLN dispersion and ethanol solution.
Spectra reported in panels C and D of Figure 2, clearly
indicate that there are no energy transfer/interference phenom-
ena both in the case of SLN-RH and SLN-CG mixtures
(panel C) nor for RH and CG co-embedded in SLN (panel D).
From a macroscopic point of view, the obtained fluores-
cent SLN have homogeneous and opaque appearance, even
if differently colored, depending on the type of fluorophore
loaded as clearly appreciable in Figure 3, showing SLN-CG
(panel A), SLN-RH (panel B) and SLN-CG/RH (panel C).
Fluorescent SLNweremorphologically examined by cryo-
TEM. In Figure 3D SLN-CG/RH are shown as an example,
since all SLN displayed a very similar morphology (data not
shown).29 Nanoparticles show flat ovoid shapes, appearing as
“wafer biscuits” when edge-on viewed. This aspect confirms
Figure 1 Absorption spectra of the fluorophore RH and CG ethanol solution.
Emission spectra in ethanol solution of RH (red line, λex= 540 nm) and CG (black
line, λex= 690 nm) and as 1:1 (w/w) mixture RH+CG measured at λex= 540 nm
(blue line) and λex= 690 nm (green line).
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previously results obtained for similar SLN loaded with single
fluorophores.29 Notably, there is no evidence of agglomerates.
Table 1 reports the mean diameters, as Z-average, and
polydispersity values of fluorescent SLN-CG/RH. A modest
increase in the mean diameter has been found throughout 2
months. In addition, the polydispersity values remain steady,
indicating a stable and homogeneous SLN population.
Concerning zeta potential, SLN CG/RH display a negative
value around −21 mV, almost unchanged within 2 months.
Notably, the negative charge of nanoparticles could contri-
bute to maintain the stability of SLN suspension.
In vivo and ex vivo Optical Imaging
Optical imaging acquisitions performed after ip administration
of fluorescent SLN revealed their biodistribution in both the
whole organism and single organs of athymic nude mice. By
the ip route, SLN diffuse across the peritoneal membrane,
which is lined with a capillary bed. The blood vessels supply-
ing and draining the abdominal viscera, musculature and
mesentery constitute a blood-filled compartment into which
SLN can rapidly diffuse from the peritoneum. Figure 4A and
B shows that, in thefirst 30min after injection, thefluorescence
emission of both SLN-CG and SLN-C/-RH rises rapidly with
a similar kinetic curve profile from the whole animal body.
After approximately 90 min, the fluorescence signal was
detectable in more defined abdominal areas. After 120 to 180
min, we could observe both SLN-CG and SLN-CG/RH accu-
mulation only in specific abdominal districts corresponding to
the liver anatomical site (Figure 4C and D). After 180 to 240
min, thefluorescent emission reached a plateau (Figure 4A and
Figure 2 Emission spectra of SLN-RH (A), SLN-CG (B), mixture of SLN-RH and SLN-CG (C) and co-loaded SLN-RH/CG (D). Emission spectra are obtained at different
excitation wavelength λex= 540 nm (dotted line) and λex= 690 nm (full line). RH spectra: red line; CG spectra: green line.
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B). The ex vivo acquisition of isolated organs confirmed the
liver as the fluorescence accumulation site (Figure 4E and F).
The other organs extracted did not show significant signal
(Figure S1). It is worth noting that isolated organswere imaged
after perfusion, which allowed us to remove fluorophore traces
from the vasculature.
The biodistribution of SLN-CG and SLN-CG/RH
(Figure 4) was similar, thus demonstrating that the interactions
with the biological environment did not induce alterations
despite the similar spectroscopic features. Therefore, the
microscopical analyses in the liverwere performed usingSLN-
CG/RH only.
Light Microscopy ex vivo Analyses
Observations at fluorescence microscopy revealed an accu-
mulation of RH signal in the cytoplasm of hepatocytes,
especially in the centrilobular area (Figure 5E–H) in compar-
ison with control samples (Figure 5A–D). No RH signal was
observed in other cell types. Accordingly, a marked increase
in hepatocytes lipid content was found in Oil Red O stained
samples of treated mice, especially in hepatocytes located
close to the centrilobular vein (Figure 6B) in comparison
with control samples (Figure 6A).
Transmission Electron Microscopy ex vivo
Analyses
When liver samples were observed at TEM, an evident accu-
mulation of lipid droplets, sometimes showing a finely
granular electron-dense border, was found in hepatocytes of
SLN-treated mice in comparison to controls (Figure 7A and
B), where the intracellular lipid content was quite low. In SLN-
treated mice, some lipid droplets were even found to be
extruded from hepatocytes (Figure 7C). No lipid droplet accu-
mulation was ever observed in other liver cells (eg, macro-
phages, endothelial cells).
In addition, hepatocytes from SLN-treated animals
showed a general loosened appearance: the nuclei were almost
devoid of heterochromatin clumps, the cisternae of the rough
endoplasmic reticulum lost their typical parallel arrangement,
and the glycogen clusters were rarefied; however, no marked
organelle damage was observed (Figure 7B andD). No sign of
cell death (eg, necrosis, apoptosis) was found. No clearly
recognizable SLN were ever observed in any cell types of
the examined liver samples.
In vitro Study
As shown by brightfield microscopy observation of sam-
ples stained with Oil Red O (Figure 8A–F), 3T3 cells
treated with SLN progressively accumulated lipid droplets
up to 24 h (Figure 8A–C), whereas no lipid increase was
Figure 3 Macroscopic appearance of SLN-CG (A), SLN-RH (B), SLN-CG/RH (C)
and cryo-TEM photomicrograph of SLN-CG/RH (D).









0 283 ± 10 0.39 ± 0.08 − 20.16 ± 1.2
1 289 ± 7 (n.s.s.) 0.39 ± 0.02 − 20.81 ± 0.7
3 280 ± 18 (<0.05) 0.34 ± 0.02 −21.34 ± 2.2
7 316 ± 16 (n.s.s.) 0.29 ± 0.01 − 21.12 ± 1.5
15 329 ± 14 (<0.05) 0.31 ± 0.03 −22.04 ± 0.9
30 327 ± 12 (<0.05) 0.33 ± 0.01 − 21.82 ± 1.3
60 320 ± 11 (<0.05) 0.32 ± 0.03 − 21.68 ± 2.1
Note: Data are the mean of five measurements ± s.d.
Abbreviation: n.s.s, not statistical significant.
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found in control cells (Figure 8D–F). TEM observations
confirmed in SLN-treated cells the occurrence of large
amounts of lipid droplets, which frequently showed
moderate electron-dense and finely granular borders
(Figure 8G). SLN were hardly detectable and only a very
limited number were found after 1 h incubation. They
showed an evident electron density and occurred free in
the cytosol (Figure 8H); some of them were found in close
proximity of lipid droplets (Figure 8G–H). After 4
h incubation, some lipid droplets were found to be
extruded from the cells (Figure 8I).
Discussion
SLN have attracted great attention in recent years as effi-
cient and potentially well-tolerated drug carriers.33–35
However, at present only poor information is available
on their systemic administration. In fact, to our knowl-
edge, the available literature on SLN administration
in vivo is based on nanoparticles loaded with active mole-
cules and/or modified to target specific organs/tissues. In
addition, no data on the SLN biodistribution in the whole
organism are available but only studies on the short-term
accumulation in the target organs have been performed
Figure 4 Plot of the kinetic uptake in the abdominal region (A, B) up to 4 h after injection; SLN biodistribution in living animals 3 h after ip injection (C, D), and fluorescent
emission in excised and perfused liver (E, F). (A, C and E) refer to SLN-CG; (B, D and F) refer to SLN-CG/RH.
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(eg,36–40). In this view, our study represents a novel con-
tribution to the evaluation of biocompatibility of blank
SLN by i) providing information on their in vivo biodis-
tribution after systemic (ip) administration in healthy mice
up to 4 h (a time sufficient for the complete elimination of
lipid nanoparticles from the organism); ii) evaluating ex
vivo the accumulation of SLN in multiple organs; iii)
analyzing the effects on histological and cytological fea-
tures of organs that proved to accumulate nanoparticles. In
addition, information on the intracellular fate of SLN
supporting in vivo and ex vivo data has been provided
by using an in vitro model.
These results correlating organismic and histologic
data have been obtained thanks to the original dual label-
ling of SLN with CG and RH, two fluorophores detectable
by optical imager and fluorescence microscopy, respec-
tively. It should be underlined that both fluorophores
were stably bound to SLN, indicating a firm association
between fluorophore and nanoparticles, as found by ultra-
centrifugation experiments followed by thin layer
chromatography.32
Fluorescence molecular tomography allows the evalua-
tion of the in vivo and ex vivo biodistribution of fluores-
cently labelled nanoparticles by enabling non-invasive
detection and quantification of fluorescence distributed
throughout the whole body of living small animals as
well as in isolated organs.41,42 The in vivo biodistribution
of SLN was monitored up to 4 h after systemic adminis-
tration and, at the last acquisition time, the fluorophore
signal was almost exclusively located in the superior abdo-
men anatomical area, corresponding to liver and spleen.
The fluorescence acquired from the isolated organs proved
to come mostly from the liver. This was confirmed by the
fluorescence microscopy analysis of liver tissue slices,
where the fluorophore signal was observed inside hepato-
cytes, especially those located in the centrilobular area.
After ip administration, the bloodstream transports the
SLN in all anatomical districts where they can be either
Figure 5 Light microscopy images of liver sections from control (A–D) and SLN-CG/RH-treated (E–H) mice. (A, E) brightfield images; (B, F) red signal from RH contained
in SLN; (C, G) blue signal from DNA stained with Hoechst; (D, H) merge of brightfield image, red and blue fluorescence. Note the red fluorescence signal inside the
hepatocytes of the treated mouse. V: centrilobular vein. Bars 50 µm.
Figure 6 Light microscopy images of liver sections from control (A) and SLN-
treated (B) mice; note the large amounts of lipid droplets in B (Oil Red O staining).
V: centrilobular vein. Bars, 100 µm.
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retained or removed by the venous and lymphatic circle,
depending on the histological and functional characteris-
tics of the tissues. The ip administration was selected
because the peritoneal wall is rich in vessels, so the admi-
nistered drugs can reach all tissues and organs following
the systemic blood circulation in a few minutes.
Specifically, by the ip route, a drug gets into the systemic
circulation mostly through hepatic portal system.
Moreover, due to lipid nature of SLN and the high dosage
volume needed for our experimental conditions, ip admin-
istration ensures a systemic distribution while avoiding
blood vessel obstruction (especially in the small tail vein
of mice).
The hepatic accumulation observed for SLN is consistent
with previous results obtained with Magnetic Resonance
Imaging on the biodistribution of paramagnetic SLN.43
Liver is known to play a key role in the removal and detox-
ification of various metabolites from the bloodstream as well
as in the processing of lipids. Accordingly, the histological
analysis of liver by Oil Red O staining revealed that hepato-
cytes from SLN-treated mice contained large amounts of
lipid droplets, especially close to the centrilobular vein. It
may be therefore hypothesized that hepatocytes massively
capture these lipid-based nanoparticles from the blood-
stream, with a consequent accumulation of lipid droplets
similar to what physiologically happens after an increased
intake of fat.44–46 Consistently, no SLN signal was detected
by optical imaging in organs not involved in lipid absorption
via mesenteric vessels, such as the spleen and lymph nodes.
TEM confirmed the occurrence of large amounts of lipid
droplets in hepatocytes from treated mice; moreover, evi-
dence of lipid extrusion was observed. Both histologic and
ultrastructural evidence therefore supports the hypothesis
that, under our experimental conditions, hepatocytes undergo
a lipid overloading due to the nanoparticle administration.
However, no sign of organelle damage or cell death (eg,
necrosis, apoptosis) was found, despite we had to administer
a relatively high concentration of SLN to allow their detec-
tion at the optical imager. As for the accumulation of the
fluorophore signal close to the centrilobular vein, it is known
that hepatocytes located in the centrilobular area are espe-
cially involved in detoxification, and accumulate toxic exo-
genous substances to be metabolized and eliminated through
the biliary route.47–49 It is therefore likely that SLN coming
from the bloodstream were internalized especially by the
centrilobular hepatocytes.
Our in vitro cell model allowed us to elucidate the intra-
cellular fate of SLN and provide an experimental explanation
for the intracellular accumulation of lipid droplets. Since 3T3
cell line is able to differentiate into adipocyte-like cells, it is
an appropriate in vitro model to investigate intracellular lipid
accumulation. It was evident that 3T3 cells progressively
accumulated - and also extruded - lipid droplets, while mor-
phologically recognizable SLN were detected in the cytosol
only in a very limited amount at the shortest incubation time.
It may be hypothesized that, as observed for other lipid-based
nanoparticles,50 SLN enter the cells by fusion with the
plasma membrane,51,52 thus explaining the absence of
Figure 7 TEM images of liver from control (A) and SLN-treated (B–D) mice. Note the high number of lipid droplets (L) in the hepatocytes of SLN-treated mouse. Some
lipid droplets showing a finely granular electron-dense border are extruded from the cell (arrow in (B); high magnification in (C). In addition, the hepatocyte in (B) shows
a loosened appearance, with euchromatic nucleus (N), dispersed glycogen clusters (asterisks) and rough endoplasmic reticulum cisternae (ER) arranged in a less orderly
pattern (D) in comparison to control (A). Bars 2500 nm (A, B); 1000 nm (C, D).
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endosomes, and then disaggregate in the cytoplasm. Their
lipid components are probably responsible for the accumula-
tion of lipid droplets, which are extruded by the cells when
exceedingly abundant. Interestingly, lipid droplets showing
the same fine granular electron-dense border as observed in
3T3 cells were found inside hepatocytes of treated mice,
sometimes during their extrusion in the extracellular milieu,
thus suggesting a similar intracellular fate. It is likely that
both 3T3 cells and hepatocytes may undergo severe stress
and even death when submitted to SLN/lipid concentrations
overcoming their physiological capacity of accumulating
lipid droplets. However, the SLN concentrations adminis-
tered under our experimental conditions proved to be safe
for both cell types.
Figure 8 Light (A–F) and transmission electron (G–I) micrographs of 3T3 cells. 3T3 cells after 1 h (A), 4 h (B) and 24 h (C) treatment with SLN: lipid droplets (stained with
Oil Red (O) progressively increase in number and size. 3T3 control cells after 1 h (D), 4 h (E) and 24 h (F) in medium without nanoparticles: only a few small lipid droplets
are visible. 3T3 cells after 1 h treatment with SLN (G, H): many lipid droplets (L) are distributed in the cytoplasm, sometimes showing a finely granular border (red arrows).
Three SLN (arrows) occur free in the cytoplasm, two of them very close to lipid droplets. After 4 h (I) treatment with SLN, some lipid droplets (L) were extruded from the
cells. Note that cytoplasmic organelles such as mitochondria (M) and endoplasmic reticulum (ER), and cell nuclei (N) are well preserved after SLN treatment. Bars 50 µm
(A–F); 500 nm (G–I).
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Taken together, our results support the systemic biocompat-
ibility and demonstrate the detailed biodistribution from the
whole organism to organs until the cell of SLN under the
experimental conditions applied in the present study. After 4
h from ip administration of 500 μL (50 mg/mL) of SLN the
only organ accumulating the nanoparticles was the liver,
probably due to its physiological role in lipid metabolism.
This induces a lipid accumulation likely due to the intracel-
lular disaggregation of nanoparticles that, however, does not
imply evident cell damage. Since systemic administration of
SLN proved to be nontoxic in the short term, long-term
studies are in progress in order to evaluate the persistence of
lipid accumulation in hepatocytes as well as possible damage
to the liver or other organs involved in excretion (eg, kidney).
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